Press release
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or Anxiety
Grant of Its Newest U.S. Patent Expands Anavex’s Compounds Intellectual Property Portfolio NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"Grant of Its Newest U.S. Patent Expands Anavex’s Compounds Intellectual Property Portfolio\nNEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 11,813,242 entitled “A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY, AND AGITATION”. This patent expands Anavex’s existing patent coverage of ANAVEX®2-73 (blarcamesine), including U.S. Patent No. 11,337,953 to cover Anavex’s leading drug candidate, ANAVEX®2-73 (blarcamesine), ANAVEX®1-41 and ANAVEX®19-144, for treating insomnia, anxiety or agitation. Insomnia-related costs in the U.S. have been estimated in 2020 to exceed $100 billion per year.1 The economic burden of anxiety in the U.S. was estimated in 2019 to be over $46.4 billion.2 The total incremental cost of just institutionalization of Alzheimer’s disease patients associated with agitation was estimated in 2019 at $4.3 billion in the U.S.3 This newest patent is expected to remain in force at least until July 2037, not including any patent term extension. Together with Anavex U.S. Patent No. 11,337,953, which is expected to remain in force at least until 2038, not including any patent term extension, the two patents provide extensive coverage of ANAVEX®2-73 (blarcamesine) for use in treating either insomnia or anxiety, used alone or in combination with ANAVEX®19-144 or ANAVEX®1-41. The two patents broadly cover a range of dosage forms in treating known co-morbidities in Alzheimer’s disease including but not limited to oral, injectable, topical, inhalable, subcutaneous, intranasal and sublingual dosage forms. “This granted USPTO patent is not only another important milestone in protecting the commercial potential of ANAVEX®2-73 (blarcamesine) and Anavex’s other lead compounds with the practical value of delivering holistic care for patients with Alzheimer’s dementia or Parkinson’s diseases, who often concurrently suffer from insomnia and/or anxiety, but along with other recent allowances, demonstrates our stro...